Drugs / Iron(II) Sulfate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07491783 Background | Mar 2026 → Dec 2027 expected | head and neck squamous cell carcinoma, malignant soft tissue neoplasm | Sichuan Enray Pharmaceutical Sciences Company | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iron(II) Sulfate | “Dosage Form: Injection Strength: 2 mL: 100 mg Dosage and Administration: Mix 0.5 mL Carbon Nanoparticle Suspension for Injection with 30 mg Iron(II) Sulfate for Injection,...” NCT07491783 ↗ |
| Route | Other | “administer intratumorally” NCT07491783 ↗ |